Skip to content

Released Jun 8, 2022, before the open

10-K filed Jun 8, 2022, 69 days after period end · 0001764013-22-000059

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$47.17Mderivedno prior Q4 2021 on fileN/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$32,956,000—
Free Cash Flowderived-$33,074,000—

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2018
Net Income-$47.17M-$450.00
EPS Diluted—$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR